What an Early Feasibility Study asks of a first-time sponsor

An Early Feasibility Study is the point at which a Class III cardiovascular program stops being a set of assumptions and becomes a set of facts. It is also the stage at which first-time sponsors lose the most time, because they arrive expecting a small clinical trial and find something structurally different.

What an EFS is. A small first-in-human study — typically ten subjects or fewer — of a device whose design is not yet final, conducted under an Investigational Device Exemption with the flexibility described in FDA’s EFS guidance. The purpose is to learn: whether the device does what the bench and animal work suggested, whether the procedure is what the engineers imagined, and what has to change before a larger study makes sense.

What it is not. It is not a pilot for a pivotal trial, and its data will not be pooled into one. It is not a route around non-clinical testing. And it is not a study you run quietly; an EFS is the stage of a program with the closest agency involvement you will ever have, which is the point.

The bargain. Under the traditional pathway, FDA expects a near-complete non-clinical package before any human is enrolled. Under the EFS framework, the agency accepts less complete non-clinical data — in exchange for four things from the sponsor: a rigorous risk analysis that names what is not yet known; a justification for why that residual uncertainty is acceptable for a small, closely monitored study; enrollment criteria tight enough to protect the subjects the uncertainty could affect; and a credible plan for how the device and protocol will be iterated as the study teaches you things. The sponsor’s job is not to argue that the device is safe. It is to demonstrate that the study is designed to be safe despite what is unknown.

Sponsors who understand this write a different IDE. The risk analysis is the center of the submission, not an appendix. Every gap in the non-clinical package is stated, and next to each gap is the reason the study can proceed without closing it.

The Pre-Submission comes first. An EFS filed without a Pre-Submission is a sponsor guessing at what FDA will require, and the guess is usually wrong in the expensive direction. The Pre-Sub is where you agree the non-clinical package, the endpoints, the subject population, the stopping rules and the monitoring plan before anyone spends money building them. It is also where the review division learns your device, so that the IDE is read by people who already understand it. For a first-time sponsor, skipping the Pre-Sub is the single most costly decision available.

The four things first-time sponsors underestimate. None of them is regulatory, and together they take longer than the submission.

Site selection. The centers you want — the ones whose investigators have done first-in-human work and whose institutional review boards have seen an EFS before — have queues, their own feasibility reviews, and their own opinions about your protocol. Identifying them is a month; getting a yes is several.

The clinical trial agreement and budget. An academic medical center negotiates its CTA and its budget as separate documents with separate offices, and neither moves quickly. Publication rights, indemnification, subject injury, and intellectual property clauses are where the time goes. Budgets are negotiated line by line. Start this the day you have a site interested, not the day the IDE is approved.

The IRB. The institution’s review board asks different questions from FDA. FDA has assessed whether the study is reasonable to conduct; the IRB assesses whether it is reasonable to conduct on their patients, with their consent form, in their hospital. Its comments arrive in their own vocabulary, on their own timeline, and they must be resolved before enrollment regardless of what FDA has said.

Investigational device logistics. A device with no US clearance enters the country under an IDE as investigational goods. It must be labeled accordingly, accounted for at the site, shipped under conditions that protect it, and cleared through customs with the right declaration. Sponsors who have never imported a medical device discover this at the port.

What “iterative” actually permits. The EFS framework anticipates that you will change the device and the protocol as you learn. It does not mean you may change them freely. There are three mechanisms — notifying the agency after the change, submitting a supplement, and obtaining prior approval — and the EFS guidance broadens what qualifies for the lighter mechanisms. Which one applies depends on whether the change affects the validity of the data, the scientific soundness of the study, or the rights and safety of subjects. Know the categories before you need them. A sponsor who has to look this up in the middle of a study has already lost weeks.

What the study produces beyond data. Three things, each worth more than the numbers. A working relationship with the review division, which has now seen your device perform and your team respond. A risk analysis that has been tested against reality, which is the foundation of the pivotal IDE. And the design inputs for the next version of the device, learned in humans rather than inferred from a bench. Sponsors who treat the EFS as a safety study alone leave most of its value on the table.

Where programs stall. Not, usually, at FDA. The agency’s clock is thirty days and it keeps it. Programs stall in the months before the submission is ready — the Pre-Sub that wasn’t filed, the risk analysis that wasn’t rigorous — and in the months after approval, at the sites, in contracts and budgets and IRB comments that nobody started early enough.

An EFS is where a Class III program is decided, because it is where the sponsor learns whether its assumptions about the device, the indication, and the agency were right. Treat it that way and it is the most productive year the program will have.